Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease-Current Background, Hopes, and Perspectives

Nonalcoholic fatty liver disease (NAFLD) represents the most common chronic liver disease worldwide, reaching one of the highest prevalences in patients with type 2 diabetes mellitus (T2DM). For now, no specific pharmacologic therapies are approved to prevent or treat NAFLD. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are currently evaluated as potential candidates for NAFLD treatment in patients with T2DM. Some representatives of this class of antihyperglycemic agents emerged as potentially beneficial in patients with NAFLD after several research studies suggested they reduce hepatic steatosis, ameliorate lesions of nonalcoholic steatohepatitis (NASH), or delay the progression of fibrosis in this population. The aim of this review is to summarize the body of evidence supporting the effectiveness of GLP-1RA therapy in the management of T2DM complicated with NAFLD, describing the studies that evaluated the effects of these glucose-lowering agents in fatty liver disease and fibrosis, their possible mechanistic justification, current evidence-based recommendations, and the next steps to be developed in the field of pharmacological innovation.

Automated summary

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, especially among patients with type 2 diabetes mellitus (T2DM). Currently, there are no approved pharmacologic therapies for NAFLD. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are being evaluated as potential candidates for NAFLD treatment in T2DM patients. Some GLP-1RAs have shown potential benefits in reducing hepatic steatosis, improving nonalcoholic steatohepatitis (NASH) lesions, and slowing down fibrosis progression in NAFLD patients.